Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

ImmVira Says IV Administration of Oncolytic Herpes Simplex Virus Shows Promise

publication date: Jul 21, 2022

Shenzhen ImmVira announced its IV oncolytic herpes simplex virus (oHSV) therapy showed promising biodistribution after completing the first three dose escalations in a US trial that enrolled patients with solid tumor cancers. The trial tested dosages from 1x106 to 1x108 PFU on 10 subjects. MVR-T3011 is a novel genetic engineered oHSV (herpes virus) that uses attenuated HSV-1 for best replication potency and safety. The candidate is a 3-in-1 oHSV containing both a PD1 mAb and IL12. ImmVira says MVR-T3011 is a next-gen design based on its oncolytic virus insights and gene recombinant technology. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital